Aucta Company Profile
✉ Email this page to a colleague
What is the competitive landscape for AUCTA, and what generic alternatives to AUCTA drugs are available?
AUCTA has four approved drugs.
There are three US patents protecting AUCTA drugs.
There are six patent family members on AUCTA drugs in four countries and eight supplementary protection certificates in five countries.
Summary for Aucta
| International Patents: | 6 |
| US Patents: | 3 |
| Tradenames: | 4 |
| Ingredients: | 4 |
| NDAs: | 4 |
Drugs and US Patents for Aucta
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aucta | MOTPOLY XR | lacosamide | CAPSULE, EXTENDED RELEASE;ORAL | 216185-002 | May 4, 2023 | RX | Yes | No | 11,883,374 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Aucta | MOTPOLY XR | lacosamide | CAPSULE, EXTENDED RELEASE;ORAL | 216185-002 | May 4, 2023 | RX | Yes | No | 12,042,474 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Aucta | MOTPOLY XR | lacosamide | CAPSULE, EXTENDED RELEASE;ORAL | 216185-001 | May 4, 2023 | RX | Yes | No | 12,042,474 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Aucta Drugs
Supplementary Protection Certificates for Aucta Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0888289 | 09C0006 | France | ⤷ Sign Up | PRODUCT NAME: LACOSAMIDE; REGISTRATION NO/DATE IN FRANCE: EU/1/08/470/001 DU 20080829; REGISTRATION NO/DATE AT EEC: EU/1/08/470/001 DU 20080829 |
| 0888289 | SPC/GB09/007 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: LACOSAMIDE AND ITS PHARMACEUTICALLY ACCEPTABLE FORMS; REGISTERED: UK EU/1/08/470/001 20080829; UK EU/1/08/470/002 20080829; UK EU/1/08/470/003 20080829; UK EU/1/08/470/004 20080829; UK EU/1/08/470/005 20080829; UK EU/1/08/470/006 20080829; UK EU/1/08/470/014 20080829; UK EU/1/08/470/015 20080829; UK EU/1/08/470/016 20080829; UK EU/1/08/470/007 20080829; UK EU/1/08/470/008 20080829; UK EU/1/08/470/009 20080829; UK EU/1/08/470/010 20080829; UK EU/1/08/470/012 20080829; UK EU/1/08/470/013 20080829 |
| 0914118 | 06C0049 | France | ⤷ Sign Up | PRODUCT NAME: DEFERASIROX OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; REGISTRATION NO/DATE IN FRANCE: EU/1/06/356/001 DU 20060828; REGISTRATION NO/DATE AT EEC: EU/1/06/356/001 DU 20060828 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
